ArticleBlood2012
Defective regulatory B-cell compartment in patients with immune thrombocytopenia.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 192 citations in OpenAlex.
- Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis.The Journal of international medical research · 2023Pooled it
- Impaired Antibody-Independent Immune Response of B Cells in Patients With Acute Dengue Infection.Frontiers in immunology · 2019Trial
- β2-adrenergic receptor agonist regulates macrophage polarization via HMGB1 in immune thrombocytopenia.Science China. Life sciences · 2026Article
- Platelet Recovery and Coexisting Conditions in Pediatric Immune Thrombocytopenia: Insights from a Tertiary Care Study.Children (Basel, Switzerland) · 2025Article
- CDKN1A as a potential target for Eltrombopag treatment in ITP and its regulation of the communication between macrophages and transitional B cells in ITP.Annals of hematology · 2025Article
- Expansion of B10 cellsInternational journal of molecular medicine · 2025Review
- High dimensional proteomic mapping of bone marrow immune characteristics in immune thrombocytopenia.Science China. Life sciences · 2024Article
- Diffuse large B‑cell lymphoma and monoclonal gammopathy secondary to immune thrombocytopenic purpura: A case report.Oncology letters · 2023Article
- Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia.Expert review of hematology · 2023Review
- Review
- How we treat primary immune thrombocytopenia in adults.Journal of hematology & oncology · 2023Review
- Adapted guideline for the diagnosis and treatment of primary immune thrombocytopenia for Chinese children (2021).Pediatric investigation · 2022Article
- Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells.British journal of haematology · 2022Article
- Efficacy and Immunomodulating Properties of Eltrombopag in Aplastic Anemia following Autologous Stem Cell Transplant: Case Report and Review of the Literature.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Immune Status and Chemokine C Receptor 7 Expression in Primary in Patients with Immune ThrombocytopeniaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2022Article
- Immune Thrombocytopenic Purpura as a Hemorrhagic Versus Thrombotic Disease: An Updated Insight into Pathophysiological Mechanisms.Medicina (Kaunas, Lithuania) · 2022Review
- Exploring the Potential of Eltrombopag: Room for More?Frontiers in pharmacology · 2022Article
- Post-therapy B Regulatory Cells Might early Predict Relapse in Hodgkin Lymphoma.Mediterranean journal of hematology and infectious diseases · 2022Article
- Increasing numbers of CD19 + CD24International journal of hematology · 2021Article
- Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia.Blood advances · 2021Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
B lymphocytes producing antiplatelet autoantibodies play a major role in autoimmune thrombocytopenia (ITP). However, certain B cells, including the human CD19(+)CD24(hi)CD38(hi) subpopulation, possess regulatory functions mediated partly by IL-10. In a cohort of chronic ITP patients with low platelet counts who consisted of patients off treatment, we found a lower frequency of CD19(+)CD24(hi)CD38(hi) in the peripheral compartment of nonsplenectomized patients (P = .03). IL-10 expression after activation was decreased in all ITP circulating CD19(+) subpopulations (P < .03), and inhibition of monocyte TNF-α expression by activated B cells was reduced in patients with platelet numbers of < 50 × 10(9) cells/L (P = .001), indicating that regulatory B cells of patients with ITP are functionally impaired in their ability to dampen monocyte activation. Interestingly, in nonsplenectomized patients whose platelet counts were elevated after treatment with thrombopoietic agents, the frequency of CD19(+)CD24(hi)CD38(hi) B cells was increased compared with those before treatment (P = .02). Altogether, these data indicate a compromised regulatory B-cell compartment as an additional defect in immune regulation in patients with chronic ITP that may be restored in responders to thrombopoietic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.